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Introduction: The introduction of biological and synthetic meshes has revolutionised the practice of
implant-based breast reconstruction (IBBR) but evidence for effectiveness is lacking. The iBRA (implant
Breast Reconstruction evAluation) study is a national trainee-led project that aims to explore the practice
and outcomes of IBBR to inform the design of a future trial. We report the results of the iBRA National
Practice Questionnaire (NPQ) which aimed to comprehensively describe the provision and practice of
IBBR across the UK.
Methods: A questionnaire investigating local practice and service provision of IBBR developed by the
iBRA Steering Group was completed by trainee and consultant leads at breast and plastic surgical units
across the UK. Summary data for each survey item were calculated and variation between centres and
overall provision of care examined.
Results: 81 units within 79 NHS-hospitals completed the questionnaire. Units offered a range of
reconstructive techniques, with IBBR accounting for 70% (IQR:50e80%) of participating units' immediate
procedures. Units on average were staffed by 2.5 breast surgeons (IQR:2.0e3.0) and 2.0 plastic surgeons
(IQR:1.0e3.0) performing 35 IBBR cases per year (IQR:20-50). Variation was demonstrated in the pro-
vision of novel different techniques for IBBR especially the use of biological (n ¼ 62) and synthetic
(n ¼ 25) meshes and in patient selection for these procedures.Research, School of Social and Community Medicine, University of Bristol, 39 Whatley Road, Clifton, Bristol, BS8 2PS.
tter).
Reconstruction Research Collaborative are PUBMED citable collaborators in this study and are listed at the end of the
r Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
S. Mylvaganam et al. / The Breast 35 (2017) 182e190 183Conclusions: The iBRA-NPQ has demonstrated marked variation in the provision and practice of IBBR in
the UK. The prospective audit phase of the iBRA study will determine the safety and effectiveness of
different approaches to IBBR and allow evidence-based best practice to be explored.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Implant-based breast reconstruction (IBBR) is the most
commonly-performed reconstructive procedure in the UK [1].
Traditionally, this has been a two-stage procedure in which a
tissue-expander is placed under the pectoral muscle at the time of
mastectomy and inﬂated over several weeks before being
exchanged for a ﬁxed-volume implant. This type of IBBR can pro-
duce good cosmetic results for patients with small to medium-
sized breasts with minimal ptosis [2]. Patients with larger or
more ptotic breasts desiring reconstruction have historically been
offered autologous tissue-based techniques, often latissimus dorsi
ﬂap reconstruction with or without an implant to achieve the
desired volume [3].
In the last ten years, the introduction of new techniques using
biological or synthetic meshes to augment the subpectoral pocket
have revolutionised the practice of IBBR. These products allow
single-stage direct-to-implant reconstruction [4] avoiding the need
for time-consuming and uncomfortable expansions and a second
operation [5]. They have also broadened the indications for IBBR so
that more women are suitable for a mesh-assisted reconstruction
than the more traditional tissue-expansion-based techniques. This
is because the mesh enlarges the subpectoral pocket improving
lower-pole projection and creating a more natural-looking, ptotic
result [6e10]. These techniques of IBBR therefore have signiﬁcant
potential beneﬁts for patients and healthcare providers.
Despite the widespread adoption of mesh-assisted IBBR into
practice, there is a lack of high-quality evidence to support the
proposed beneﬁts of these techniques [11]. Recent events leading to
the temporary withdrawal of Strattice in France [12] due to
excessively high rates of complications have highlighted the need
for robust evaluation of mesh-assisted IBBR to protect patients and
prevent potentially inferior interventions or products becoming
established in practice. Randomised trials (RCTs) are needed, but
to-date only ﬁve RCTs have been attempted; three comparing IBBR
with and without mesh and two comparing different products. Of
the three comparing IBBR with and without mesh, the ﬁrst, a
North-American trial, compared two-stage IBBR with and without
biological mesh [13]. This recruited slowly and was closed early to
accrual by the Data Safety Monitoring Board. The second [14], from
the Netherlands, compared two-stage IBBR with single-stage
direct-to-implant reconstruction with acellular dermal matrix
(ADM). This suggested unacceptably high complication rates in the
ADM group (29% vs 5%) and the trial was stopped due to safety
concerns. The complication rates seen in the ADM group, however,
do not reﬂect those seen in observational studies in the UK [15] and
it has been suggested that the results may reﬂect the surgeons'
initial learning curve rather than problems with the technique [16].
A third Canadian study also comparing standard two-stage
expander-implant reconstruction and single-stage mesh-assisted
IBBR is yet to report [17]. Two further studies have compared
different meshes. One North American trial compared two human
ADMs [18] and demonstrated no difference between products and a
second trial from Europe compared biological and synthetic
meshes [19]. This latter study, although reported as a pilot-study,
was in fact a small trial that was insufﬁciently well-designed toidentify differences between the treatment groups [20]. To date,
data from the UK comprise heterogeneous, often single-centre
cohort studies or case-series [21,22], much of which has been re-
ported only in abstract form [23,24]. There is therefore now a need
for a well-designed and conducted multi-centre pragmatic trial to
inform UK practice.
Before such a trial can be conducted, it is necessary to deﬁne the
research question and determine the optimal study design. It is
therefore important to understand the current practice of IBBR.
Uncertainties relating to numbers of procedures being performed;
the numbers of surgeons and centres offering each technique; the
products being used and selection criteria for different techniques
need to be addressed. It is also vital to explore which study designs
would be the most acceptable to both patients and surgeons to
optimise participation and recruitment. Pilot work is required to
establish these parameters before a trial can be considered.
The iBRA (implant Breast Reconstruction evAluation) study is a
trainee collaborative project that aims to explore the practice and
outcomes of IBBR to inform the design and conduct of a future trial
[25]. We report the results of the ﬁrst phase of the iBRA Study, a
National Practice Questionnaire (NPQ) which aimed to survey
breast and plastic surgical units across the UK to comprehensively
describe the current practice of IBBR.2. Methods
The national practice questionnaire (NPQ, Appendix 1) was
developed in February 2014 bymembers of the iBRA steering group
based on a comprehensive review of the literature [11], current
professional guidelines [26,27] and clinical expertise. It included
sections evaluating the availability of different approaches to breast
reconstruction and the numbers of surgeons performing recon-
structive techniques at each unit; volumes of implant-based pro-
cedures performed; availability and use of different meshes and
techniques and selection criteria for each procedure type. Re-
spondents were also asked whether they felt their practice of IBBR
had changed following the introduction of mesh-assisted tech-
niques and if so, what the change had been. The questionnaire was
piloted with surgeons at two hospitals to ensure face and content
validity prior to circulating the questionnaire nationally.
All breast and plastic surgical units performing mastectomy
with or without immediate breast reconstruction in the UK were
eligible for inclusion. Trainees were invited to participate via the
Mammary Fold breast trainees' group, the Reconstructive Surgery
Trials Network (RSTN) and the National Trainee Research Collabo-
rative (NTRC). The professional associations (Association of Breast
Surgery (ABS) and British Association of Plastic, Reconstructive and
Aesthetic Surgeons (BAPRAS)) endorsed the study and encouraged
units to participate. Each participating trainee was required to
identify a consultant lead in their unit. The trainee completed the
questionnaire with this consultant ensuring that responses re-
ﬂected the practice of the unit as a whole, rather than that of an
individual surgeon.
Study data were collected and managed using REDCap elec-
tronic data capture tools hosted at University of Edinburgh [28].
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Descriptive summary statistics were calculated for each survey
item to evaluate the availability, volume and indications for each
type of IBBR. Categorical data was summarised by counts and
percentages. Continuous data was summarised by median, inter-
quartile range (IQR) and range. No data imputation methods were
used for itemswith no response andwhen a unit did not complete a
speciﬁc section of the questionnaire, it was assumed that the unit
did not offer that approach. Statistical Analysis Software (SAS®
9.1.3; SAS Institute Inc., Cary, NC, USA) was used for all analyses.
Free text responses were collated and analysed using a content
analysis approach.
3. Results
3.1. Participation
Between May 2014 and November 2015, 81 responders from 79
NHS hospitals completed the NPQ. Two hospitals had independent
responses from the breast and plastic surgical units. Each of these
was considered an independent unit with different practices
despite stemming from the same organisation. 67 of 144 (47%)
breast units and 14 of 53 (26%) plastic units in the UK participated
in the study.
3.2. Unit demographics
Unit demographics are shown in Table 1. 79/81 (98%) units
speciﬁed the types of breast reconstruction that their unit offered.
All (79/79, 100%) offered patients implant-based techniques and
most offered latissimus dorsi ﬂaps (76/79, 96%) and therapeutic
mammaplasty (77/79, 97%). Almost half of units provided an on-
site free ﬂap service with 43% (34/79) offering DIEP (deep inferior
epigastric perforator) ﬂaps (Table 1).
Participating units were staffed by a median of three full-time
equivalent (FTE) breast surgeons (IQR 2.0e3.8), 2.5 of whom per-
formed reconstructive surgery (IQR 2.0e3.0). Of the participating
breast units, 30/67 (45%) had access to plastic surgeons within the
unit (e.g. plastic surgical clinics but no on-site access to free-ﬂap
reconstruction) and 23/67 (34%) had comprehensive on-site plas-
tic surgical services with access to free-ﬂaps within the unit.
3.3. Practice of implant-based reconstruction
Participating units reported that IBBR represented approxi-
mately 70% (IQR 50e80%) of their reconstructive case load and
performed median of 35 cases per year (IQR 20-50) (Table 1). The
number of IBBR per year performed by each participating unit is
shown in Fig. 1. Marked variability, however was demonstrated in
the types of IBBR offered. Dermal-sling techniques were the most
widely-available with over 80% (66/79, 84%) of responding units
performing this technique. Three-quarters of units (59/79, 75%)
offered patients acellular dermal matrix (ADM)-assisted recon-
struction, but exceptional funding was required on an individual
patient basis at almost 20% of centres (11/79) and less than a
quarter of units (n ¼ 19/79, 24%) performed synthetic mesh-
assisted procedures. Strattice (53/61, 87%) and SurgiMend
(n ¼ 33/62, 53%) were the most commonly-used biological meshes
and TiLOOP was the most frequently-used synthetic mesh, but a
range of different products were reported (Table 1).
The majority of respondents reported that the introduction of
the mesh-assisted procedures had changed their reconstructive
practice. Almost two-thirds (48/72, 67%) felt that the ratio of im-
mediate implant-based to autologous reconstruction had increasedas a result of the new techniques largely due to increased in-
dications for implant-based procedures and almost half (32/72,
44%) reported performing more immediate breast reconstruction
since the new techniques had been introduced.
3.4. Patient selection for new techniques of implant-based breast
reconstruction
There was signiﬁcant variation in patient selection for different
techniques across the responding units. The majority of units (54/
66, 82%) reported offering dermal-sling techniques to women with
ptotic breasts but there was a lack of consensus regarding other
aspects of patient selection. Previous radiotherapy to the breast, for
example was considered an absolute contraindication to the tech-
nique by almost 40% (25/66, 38%) of responding units; a relative
contraindication by approximately half of units (32/66, 48%) and
not a contraindication by almost 10% (5/66, 8%), demonstrating
signiﬁcant variation in practice (Fig. 2).
Similar lack of consensus was demonstrated regarding the se-
lection criteria for biological and synthetic mesh-assisted tech-
niques. Previous radiotherapy to the breast, smoking and large
breasts were the most commonly reported absolute contraindica-
tions for biological meshes, but signiﬁcant numbers of units re-
ported offering this technique to women in these situations either
routinely or on a case-by-case basis (Fig. 3). Patient selection for
synthetic mesh-assisted techniques was similarly inconsistent
although previous radiotherapy, smoking, obesity and the likely
need for post-mastectomy radiotherapy were the most frequently
reported reasons for caution when considering this approach
(Fig. 4).
4. Discussion
This study has provided a valuable insight into the current
practice of IBBR in the UK. The procedure is widely-available and
represents a signiﬁcant proportion (70%) of units' reconstructive
workload suggesting that greater volumes of IBBR are now being
performed than have been previously reported [1]. Units have
sufﬁcient expertise to perform implant-based surgery with a me-
dian of 2.5 FTE reconstructive breast surgeons and 2.0 FTE plastic
surgeons performing a median of 35 immediate implant-based
cases per unit per year. Although dermal-sling techniques were
widely-available, only 75% of centres offered biological mesh with
approximately 20% requiring exceptional funding and just 25%
performed synthetic mesh-assisted procedures. The most
frequently-used products were Strattice, SurgiMend and TiLOOP
but overall, a wide range of meshes were reported. The majority of
respondents reported that their reconstructive practice had
changed following the introduction of mesh-assisted techniques.
Two-thirds reported performing a higher ratio of implant to
autologous reconstructions and 40% described an increase in rate of
immediate reconstruction overall which was probably related to
the availability of these techniques. Patient selection, was shown to
be highly-variable between centres with a lack of consensus
regarding absolute and relative contraindications for dermal-sling
and mesh-assisted procedures. Further work is needed to explore
the impact of patient selection on the outcome of IBBR to determine
best practice and improve outcomes for patients.
This survey suggests that the availability and practice of IBBR in
the UK is evolving and that the introduction of mesh-assisted
techniques have resulted in more implant-based surgery being
performed. Participating units estimated that 70% of their imme-
diate reconstructions were implant-based which is almost twice
that reported in the National Mastectomy and Breast Reconstruc-
tion Audit [1]. This may reﬂect the underrepresentation of plastic
Table 1
Characteristics of participating units.
Unit characteristic N ¼ 79
Types of breast reconstruction offered
Implant-based reconstruction 79 (100)
Pedicled ﬂaps
Latissimus dorsi 76 (96)
Pedicled TRAM 31 (39)
Free ﬂaps
DIEP 34 (43)
Other autologous (e.g SGAP, IGAP, TUG, SIEA) 24 (30)
Therapeutic mammoplasty 75 (95)
Revisional surgery 77 (97)
Number of staff performing breast and reconstructive surgery
Breast surgery
Number of consultant surgeons with an interest in breast surgery (FTE, median, IQR, range) 3.0 (2.0e3.8) (0.0e7.0)
Number of consultant breast surgeons who perform reconstructive surgery (FTE, median, IQR, range) 2.5 (2.0e3.0) (0.0e7.0)
Plastic surgery
Number of consultant plastic surgeons with an interest in breast surgery (FTE, median, IQR, range) 1.0 (0e3.0) (0.0e21.0)
Number of consultant plastic surgeons who perform reconstructive surgery (FTE, median, IQR, range) 2.0 (1.0e3.0) (0.0e10.0)
Number of immediate implant-based breast reconstructions performed per year (median, IQR, range) 35 (20-50) (0-230)
Percentage of immediate breast reconstructions that are implant-based Med (IQR)
70.0 (50.0e80.0)
Approaches to implant-based reconstruction offered n (n/N%), N ¼ 79
Standard 2 stage submuscular placement 60 (75.9)
Reduction pattern with dermal sling 66 (83.5)
Acellular dermal matrix assisted reconstruction 59 (74.7)
Other non-dermal biological-assisted reconstruction 19 (24.1)
TiLOOP assisted reconstruction 19 (24.1)
Other synthetic assisted reconstruction 8 (10.1)
Types of biological mesh used n (n/N%), N ¼ 62
Strattice 53 (85.5)
SurgiMend 33 (53.2)
Veritas 8 (12.9)
XCM 5 (8.1)
Seri 4 (6.5)
BioDesign 3 (4.8)
Permicol 3 (4.8)
Native 2 (3.2)
Other 1 (1.6)
Types of synthetic mesh used (n ¼ 25) n (n/N%), N ¼ 25
TiLOOP 20 (80.0)
TiGR 1 (4.0)
DIEP e deep inferior epigastric perforator; FTE e full time equivalent; IQR e interquartile range; TRAM e transverse rectus abdominus myocutaenous ﬂap.
Fig. 1. Number of immediate implant-based breast reconstructions performed per year by participating unit.
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Fig. 2. Patient selection for dermal sling procedures (n ¼ 66).
Fig. 3. Patient selection for biological mesh-assisted procedures (N ¼ 62).
S. Mylvaganam et al. / The Breast 35 (2017) 182e190186surgical units in the study, but reinforces the views of study par-
ticipants that autologous reconstruction rates and in particular la-
tissimus dorsi ﬂap-based reconstruction, have decreased due to the
introduction of mesh-assisted procedures, primarily as more
women are now considered suitable candidates for IBBR. These
ﬁndings may also reﬂect increased willingness to offer the pro-
cedure as recent data suggests that reconstruction rates, overall,
have increased [29]. Previous surveys have suggested that only 40%
of breast surgeons perform reconstructive surgery [30]. This work
suggests that this proportion has increased signiﬁcantly with
responding centres reporting a median of 3.0 FTE breast surgeons
per unit, 2.5 of whom were willing to offer reconstructive tech-
niques. This may reﬂect advanced training programmes such as theUK National Oncoplastic Fellowship scheme and subsequent
dissemination of the techniques as fellows become trainers.
Another explanation is that only centres engaged in reconstruction
have participated in the study. This would be more consistent with
recent ﬁndings that demonstrate that the increase in the rate of
breast reconstruction nationally is due to units with already high
rates of reconstruction performing more [29].
The lack of consensus regarding patient selection for mesh-
assisted IBBR was unanticipated and of concern. The ABS/BAPRAS
ADM guidelines outline areas of caution for the use of biological
meshes such as in smokers, womenwith a bodymass index of more
than 30; large breasts of greater than 600 g and in women who
have had previous breast/chest wall radiotherapy [27]. The
Fig. 4. Patient selection for synthetic mesh-assisted procedures (N ¼ 25).
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ported variations in practice may reﬂect this. It is also unclear
whether these guidelines can be extrapolated to other non-dermal
biological products or to synthetic meshes such as TiLOOP as there
is very little published data to support practice [31e34]. Smoking
and obesity, however, have been shown to increase rates of implant
loss in traditional two-stage reconstruction [35] and there is no
apparent reason why biological or synthetic mesh may inﬂuence
this. Radiotherapy, before or after implant reconstruction has also
been shown to lead to high rates of capsular contracture and
decreased patient satisfaction [36]. Recent data to suggest that
ADM may offer protection against the adverse effects of radio-
therapy [37,38] may explain why the majority of centres do not
consider this to be a contraindication tomesh-assisted IBBR. Data to
support the proposed beneﬁts, however are limited [39]. Further-
more, it is unclear if and how potential risks are discussed with
patients making decisions about breast reconstruction and why
surgeons differ so markedly in which patients they would consider
suitable for different techniques. It is possible that more experi-
enced surgeons feel more conﬁdent offering IBBR to high risk pa-
tients such as smokers or those with a high BMI but further
research is needed. Well-designed prospective studies and ideally
trials are required to determine best practice and allow predictors
for complications to be explored.
This study has limitations. Firstly, it is a practice survey and
actual practice may differ signiﬁcantly from that reported. For
example, surgeons may report offering mesh-assisted IBBR to
smokers to avoid being considered prejudiced against this group
when clinically, they would take this and other risk-factors such as
obesity and previous radiotherapy into consideration in their
decision-making. In addition, although trainee leads were
instructed to complete the questionnaire to reﬂect the practice of
the unit, rather than an individual, it is possible that the responses
were skewed by the views of the lead consultant completing the
questionnaire. The response rates were relatively low, particularly
among plastic surgical units and only 41% of breast units and 23% of
plastic surgical units completed the survey. This was a trainee
collaborative project so the lack of response may reﬂect the lack oftraineesmotivated to engage in the study, a lack of awareness of the
project and also the novelty of the methodology in breast and
plastic surgical studies. The lower engagement of plastic surgical
units, however, is likely to reﬂect the fact that in the UK, plastic
surgeons do not perform signiﬁcant amounts of immediate IBBR as
sufﬁcient numbers of breast surgeons are now prepared to offer the
technique without the need for referral. The low response rate,
however does raise the issue of response bias as non-participating
units may not offer IBBR or may practice in a different way. Recent
work has suggested that reconstruction rates vary signiﬁcantly by
cancer network and that although rates of immediate breast
reconstruction have increased over time, these have increased
predominantly in the centres that were already performing larger
volumes of reconstructive surgery rather than those who did not
offer that approach [29]. The aim of this survey, however was to
determine the numbers of surgeons that were performing mesh-
assisted IBBR; the volumes of cases performed; the techniques
used and the selection criteria for different techniques to inform
the design of a trial. It also aimed to engage centres in the need for
evaluation as a preliminary step to trial participation. The data
suggest the survey has mainly been completed by high-volume
centres and those with on-site plastic surgical expertise who
would form the ideal network to participate in future research
studies. Finally, this is a rapidly-evolving area with new mesh
products being launched and new techniques such as prepectoral
reconstruction [40] starting to develop and any future trial must
take this into account. Despite these limitations, the survey has
demonstrated signiﬁcant variation in practice among centres per-
forming immediate IBBR surgery in the UK.
High-quality evidence is therefore urgently needed to inform
the practice of IBBR and to improve outcomes for patients. This
survey is part of iBRA, a prospectivemulticentre study to inform the
feasibility, design and conduct of an RCT comparing new ap-
proaches to IBBR [25]. iBRA has recruited over 2000 patients from
75 centres and as such is the largest prospective multicentre study
of new approaches of IBBR worldwide. The iBRA study will provide
an important resource for hypothesis generation and allow pre-
dictors of complications such as implant loss to be explored and
S. Mylvaganam et al. / The Breast 35 (2017) 182e190188best practice established.
Future study designs will be informed by the iBRA data, but if
this suggests equivalence between mesh-assisted techniques, an
RCT comparing biological and synthetic products may be valuable
given the signiﬁcant cost differential (£1800 vs £200) between the
products. A small Austrian RCT comparing TiLOOP and the ADM,
Protexa, suggests that this design may be acceptable [19,20], but as
only 25% of units currently offer synthetic mesh-assisted proced-
ures in the UK, more units would need to adopt the technique for
such a trial to be feasible in this setting. Other potential study de-
signs may include pre-pectoral vs subpectoral implant placement
as products such as BRAXON are gaining in popularity and there
may be beneﬁts to a muscle-sparing approach [40]. Outcomes of
such approaches are lacking and preliminary safety data is needed
before a trial could be considered. Further feasibility work is
therefore required to build on the iBRA data to establish the optimal
design, comparators and outcome selection for a future trial.
5. Conclusions
The iBRA-NPQ has provided a valuable insight into the current
practice of IBBR in the UK. It has demonstrated that the uptake and
use of implant-based procedures has increased; summarised se-
lection criteria for different techniques and shown that biological,
rather than synthetic meshes are predominantly used. Practice,
however, is highly variable and reasons for these variations are
unclear. There is therefore a need for high-quality evidence to
determine best practice and help patients and surgeons makemore
informed decisions about surgery. This survey is an important ﬁrst
step in developing a well-designed RCT to address the current
uncertainties in IBBR and as such is represents a signiﬁcant
contribution to establishing evidence-based reconstructive practice
in this rapidly-evolving ﬁeld.
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